Mon, Jul 29|
Davio's Northern Italian Steakhouse
LYNPARZA Maintenance Therapy: The Only PARPi FDA-approved in First-line Maintenance for Women with BRCAm*
LYNPARZA is now the ONLY PARPi FDA-approved in first-line maintenance for women with sBRCA*- and gBRCA-mutated† advanced ovarian cancer, following response to platinum-based chemotherapy.
Time & Location
Jul 29, 2019, 6:00 PM
Davio's Northern Italian Steakhouse, 75 Arlington St, Boston, MA 02116, USA
About The Event
LYNPARZA Maintenance Therapy: The Only PARPi FDA-approved in First-line Maintenance for Women with BRCAm* Advanced Ovarian Cancer in Complete or Partial Response to Platinum-based Chemotherapy
THOMAS KRIVAK, MD
RSVP is required by 07/26/2019.
To register or for more information, contact
Katie Naylor at email@example.com or (203) 980-2353
*An FDA-approved test for the detection of tumor BRCA gene mutation for the first-line maintenance treatment of advanced † ovarian cancer is not currently available. 1
As determined by an FDA-approved companion diagnostic.
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
First-Line Maintenance BRCAm Advanced Ovarian Cancer
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
IMPORTANT SAFETY INFORMATION
There are no contraindications for LYNPARZA.
WARNINGS AND PRECAUTIONS
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in <1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The duration of therapy in patients who developed secondary MDS/AML varied from <6 months to >2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy, and some also had a history of more than one primary malignancy or of bone marrow dysplasia.
Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly